June 2023

The clinical results obtained with the new mannan-conjugated allergoids for immunotherapy against birch pollen allergy have been presented in Hamburg (Germany) during the annual EAACI congress. These studies include the first phase 3 results showing their safety and efficacy.
More info

May 2023

The results obtained with MV140 in North American patients with recurrent uncomplicated urinary tract infections were presented at the annual meeting of the American Urological Association in Chicago. The study conducted in North America (Canada) under real-world conditions indicates that MV140 has a high degree of efficacy and safety in the prevention of this type of infection.
More info

April 2023

INMUNOTEK has sponsored the ERS (European Respiratory Society) Research Seminar that has taken place in Berlin with the title "Preventing asthma - are we ready to translate epidemiological and mechanistic studies into reality?" Leading researchers in the field were invited to present their latest results with new therapeutic approaches such as that offered by mucosal bacterial immunotherapy.
More info

April 2023

Biomedicines (MDPI) publishes the results of a long-term follow-up study in patients with autoimmune diseases under immunosuppressive therapy who had previously been treated with MV130 or MV140 to prevent recurrent respiratory and/or urinary tract infections. The results indicate that the clinical benefit, in terms of a lower frequency of infections compared to the baseline period, can last up to 3 years after discontinuation of treatment.
More info

March 2023

The first results of a Phase 3 clinical trial conducted with polymerized allergoids conjugated with mannan have been presented at the AAAAI meeting held last February 24-27 in San Antonio, Texas. These preparations represent a new generation of allergen immunotherapy targeting dendritic cells developed by INMUNOTEK.
More info

February 2023

Pathogens (MDPI) publishes a comprehensive literature review on MV140, a sublingual mucosal bacterial vaccine produced by INMUNOTEK. MV140 is indicated for immunoprophylaxis of recurrent uncomplicated urinary tract infections.
More info

February 2023

New concepts in allergen-specific immunotherapy arising from discoveries related to the memory of innate immunity are reviewed in Clinical & Experimental Allergy. An analogy is drawn between trained immunity-based vaccines (TIbV) and trained immunity-based allergen vaccines (TIbAV) when the latter have, in addition to allergens, components that induce the training of innate immunity cells.
More info

December 2022

The journal Current Opinion in Allergy and Clinical Immunology publishes a review on recent advances in the prevention of viral respiratory infections in young children by bacterial immunotherapy based on the induction of trained immunity. These infections are a frequent cause of bronchiolitis and wheezing in young children.
More info

November 2022

The result of the combination of Candida albicans (V132) with the polybacterial vaccine MV140 against recurrent urinary tract infections has been published in Frontiers in Immunology. This research is a continuation of a previous study and aims to deepen the immunological mechanisms of V132+MV140, a vaccine oriented to the treatment of recurrent infections of the genito-urinary tract.
More info

October 2022

An interesting epidemiological study has been published in the Journal of Asthma and Allergy on pollen sensitisation profiles in a population with identical exposure but different origins in order to assess the influence of environmental and ancestral factors. The study was carried out in a town in Murcia (Spain) on the resident population of Spanish and Moroccan origin.
More info